Navigation Links
Jennerex to Present Final Survival Data From Randomized Phase 2 Clinical Trial of JX-594 in Advanced Liver Cancer at American Association for the Study of Liver Diseases Annual Meeting
Date:11/2/2011

SAN FRANCISCO, Nov. 2, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, today announced that final data from its Phase 2 randomized clinical trial in advanced liver cancer patients will be presented on Monday, November 7, 2011 at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) taking place November 4-8, 2011 in San Francisco, California.  These data, evaluating multi-dose administration of JX-594 in U.S., Korean and Canadian patients with advanced liver cancer, were selected for an oral presentation in the late-breaking oral session of the conference.

The presentation details are as follows:

Abstract Title: "A Randomized, Controlled Phase 2 Clinical Trial of JX-594, a Targeted Multi-Mechanistic Oncolytic Poxvirus, in Patients with Advanced Hepatocellular Carcinoma: Final Data." (Abstract #LB1)
Presenter: Tony Reid, M.D., Ph.D., professor of medicine, hematology/oncology, director of clinical investigation, and the tumor growth, invasion and metastasis program, Moores UCSD Cancer Center at the University of California, San Diego
Session: Late-Breaking Oral Session, November 7, 2011, 2:45 p.m. PT

JX-594: A Multi-Mechanistic Approach To Targeting Cancer

JX-594 is a proprietary, engineered oncolytic virus that is designed to selectively target and destroy cancer cells. JX-594 is designed to attack cancer through three diverse mechanisms of action: 1) the lysis of cancer cells through viral replication, 2) the shutdown of the blood supply to tumors through vascular targeting and destruction, and 3) the stimulation of the body's immune response against cancer cells, i.e., active immunotherapy. Phase 1 and Phase 2 clinical trials in multiple cancer types to date have shown that JX-594, delivered either directly into
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jennerex Publishes Clinical Data in Journal, Nature, Demonstrating Intravenous Delivery of Multi-Mechanistic Cancer-Targeted Oncolytic Poxvirus JX-594 to Tumors
2. Jennerex Reports Positive Mechanistic Proof-of-Concept Clinical Trial Results Using JX-594 to Treat Metastatic Melanoma
3. Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer
4. Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting
5. Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
6. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
7. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
8. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
9. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
10. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
11. Jennerex Closes $5 Million First Tranche of Series C Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Biofertilizers stimulate microbial activities in soil. ... phosphorous through the activities in the soil or in ... to the stress on reducing environmental pollution and on ... defines and segments the bio fertilizers market with analysis ...
(Date:1/22/2015)... Shimadzu Scientific Instruments today announces ... spectrophotometer. Offering wavelength scanning from 190 to 1,100 ... applications in a variety of industries, including environmental, ... UV-1280 enables intuitive operation, while the enhanced validation, ...
(Date:1/22/2015)... (PRWEB) January 21, 2015 Cambridge Semantics, the ... technology, today announced that 2014 was a record-breaking year across ... capabilities of the Anzo Smart Data Platform and our Smart ... utilize insights from diverse data which led to record growth ...
(Date:1/22/2015)... Pipette.com has added the Eppendorf Centrifuge ... of Eppendorf products. , The Eppendorf Centrifuge 5424/5424 R ... R and receive the following:, ,     Free ... Eppendorf Reference 2 ,     3 Free boxes ...
Breaking Biology Technology:Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 2Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 3Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 4Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2Cambridge Semantics Announces Record Results for 2014 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2
... Computing Workstations with Unique Integration ... Patients, COLUMBUS, Ohio, Feb. 26 ... healthcare technology solutions for the,long-term and acute ... with McKesson Automation, Inc., a division of ...
... CV Therapeutics,Inc. (Nasdaq: CVTX ) today reported financial ... 2007., For the quarter ended December 31, 2007, the ... share. This compares to a net loss of,$68.1 million, or ... $34.2,million, or $0.58 per share, for the prior quarter ended ...
... BioSpace, the world,s leading,online bioscience job board community ... biotechnology and pharmaceutical job seekers to the,Genetown Career ... Thirty-six bioscience companies exhibited at the event ... as well as the,quantity of the candidates. "The ...
Cached Biology Technology:Artromick Aligns with McKesson to Enhance Medication Safety at the Patient's Bedside 2Artromick Aligns with McKesson to Enhance Medication Safety at the Patient's Bedside 3CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 2CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 3CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 4CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 5CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 6CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 7CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 8BioSpace Boston Career Fair Attracts over 900 Bioscience Candidates 2
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ...  report to their offering. One major ... With continuous advances in technology, it is important to ...
(Date:12/11/2014)... Dec. 10, 2014  Data Sciences International (DSI), the ... a new series of digital telemetry implants to ... M series, part of the PhysioTel™ Digital platform, ... possible physiologic data when incorporating functional endpoints into ...
(Date:12/10/2014)... 9, 2014  Wake Forest Baptist Medical Center today announced plans ... Medicine. Funding for this $50 million capital project is part ... next summer. The medical education building will ... Company complex, adjacent to 525@vine in Wake Forest Innovation Quarter. ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... showing off the powers of new high-resolution 3-D imaging, ... sorts newly synthesized proteins for transport inside and outside ... according to research to be presented on Sunday, Dec. ... annual meeting in New Orleans. With conventional microscopy ...
... the outstanding work of five young researchers from China, ... IOF Young Investigator Awards, valued at 1,000 USD each, ... to the 4th Asia-Pacific Osteoporosis Meeting by researchers under ... at the Hong Kong Convention and Exhibition Centre, is ...
... level of DNA -- one amino acid on one gene -- ... different amino acid on the same gene in your friend,s body ... at Duke University. There are about 400 genes coding for ... Project, there are more than 900,000 variations of those genes. These ...
Cached Biology News:High-resolution 3-D imaging draws new picture of Golgi's whereabouts during cell division 2Young investigators awarded for research excellence at Hong Kong meeting 2No 2 people smell the same 2
... anti-phospho-FAK (Ser843) ... acid region encompassing the human, mouse, ... Accession Number: NM_153831 ... Routinely evaluated by immunoblot. ...
Molecular Biology grade. Ideally suited for DNA and RNA separation and recovery. High gel strength. Gelling temp. 36C. Melting temp. 88C. EEO: 0.05-0.13 Resolution 0.2-40 kb; Rnase/Dnase: none detec...
Rabbit polyclonal to Quinolinic acid ( Abpromise for all tested applications). Antigen: Synthetic quinolinic acid conjugated to bovine serum albumin....
Phospho-YAP (Ser127) Antibody Ship: Hot Store: -20 C...
Biology Products: